Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MIST
MIST
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MIST News
Milestone Pharmaceuticals Reports Q4 and FY 2025 Results with CARDAMYST Updates
Mar 23 2026
NASDAQ.COM
Milestone Pharmaceuticals Earnings Report Preview
Mar 20 2026
Newsfilter
Milestone Pharmaceuticals Reports Q4 2025 Earnings and CARDAMYST Launch
Mar 20 2026
Yahoo Finance
Milestone Pharmaceuticals Reports FY Results
Mar 20 2026
seekingalpha
Major Earnings Reports Expected on Friday
Mar 19 2026
seekingalpha
CARDAMYST Nasal Spray Now Available at Retail Pharmacies
Jan 26 2026
Newsfilter
Milestone Pharmaceuticals (MIST) Receives EMA Review for Etripamil Nasal Spray
Jan 07 2026
NASDAQ.COM
Aptar Launches CARDAMYST Nasal Spray to Address Needs of 2 Million PSVT Patients
Dec 17 2025
Businesswire
Aptar Launches CARDAMYST Nasal Spray for PSVT Treatment
Dec 17 2025
Newsfilter
MIST Achieves Landmark Approval: FDA Greenlights First Self-Administered Nasal Spray for PSVT
Dec 13 2025
NASDAQ.COM
FDA Grants Approval for Milestone Pharma's CARDAMYST, the First Self-Administered Therapy for PSVT
Dec 13 2025
NASDAQ.COM
Milestone Pharmaceuticals Receives FDA Approval for CARDAMYST to Treat PSVT
Dec 13 2025
Globenewswire
Milestone Pharmaceuticals Receives FDA Approval for CARDAMYST, Benefiting Over 2 Million PSVT Patients
Dec 13 2025
Newsfilter
Milestone Pharma Awaits FDA Decision on CARDAMYST, Stock Under Scrutiny
Dec 05 2025
NASDAQ.COM
Milestone Pharmaceuticals Grants 30,000 Equity Awards to Attract New Employees
Dec 02 2025
Globenewswire
Milestone Pharmaceuticals Grants 30,000 Options to Attract New Employees
Dec 02 2025
Newsfilter
Show More News
